GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » E10

BCTX (BriaCell Therapeutics) E10 : $-101.12 (As of Oct. 2024)


View and export this data going back to . Start your Free Trial

What is BriaCell Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

BriaCell Therapeutics's adjusted earnings per share data for the three months ended in Oct. 2024 was $-3.300. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-101.12 for the trailing ten years ended in Oct. 2024.

During the past 3 years, the average E10 Growth Rate was 30.10% per year. During the past 5 years, the average E10 Growth Rate was 18.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of BriaCell Therapeutics was 30.10% per year. The lowest was 1.50% per year. And the median was 8.55% per year.

As of today (2025-03-14), BriaCell Therapeutics's current stock price is $3.84. BriaCell Therapeutics's E10 for the quarter that ended in Oct. 2024 was $-101.12. BriaCell Therapeutics's Shiller PE Ratio of today is .


BriaCell Therapeutics E10 Historical Data

The historical data trend for BriaCell Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics E10 Chart

BriaCell Therapeutics Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -356.81 -335.24 -319.17 -319.91 -105.73

BriaCell Therapeutics Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -299.73 -301.81 -293.87 -105.73 -101.12

Competitive Comparison of BriaCell Therapeutics's E10

For the Biotechnology subindustry, BriaCell Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Shiller PE Ratio falls into.



BriaCell Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BriaCell Therapeutics's adjusted earnings per share data for the three months ended in Oct. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Oct. 2024 (Change)*Current CPI (Oct. 2024)
=-3.3/127.8378*127.8378
=-3.300

Current CPI (Oct. 2024) = 127.8378.

BriaCell Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201501 -141.405 98.209 -184.065
201504 -37.429 99.710 -47.987
201507 -23.257 100.579 -29.560
201510 -34.420 100.500 -43.783
201601 -32.198 100.184 -41.085
201604 -35.849 101.370 -45.209
201607 -30.270 101.844 -37.996
201610 -33.546 102.002 -42.043
201701 -34.343 102.318 -42.909
201704 -65.961 103.029 -81.844
201707 -141.308 103.029 -175.335
201710 -35.080 103.424 -43.361
201801 -36.479 104.056 -44.816
201804 -35.038 105.320 -42.529
201807 104.653 106.110 126.082
201810 -22.074 105.952 -26.634
201901 -33.237 105.557 -40.253
201904 -28.933 107.453 -34.422
201907 -39.612 108.243 -46.783
201910 -27.455 107.927 -32.520
202001 -29.626 108.085 -35.040
202004 -10.491 107.216 -12.509
202007 -20.003 108.401 -23.590
202010 -8.100 108.638 -9.531
202101 -4.500 109.192 -5.268
202104 9.450 110.851 10.898
202107 -15.824 112.431 -17.992
202110 -27.150 113.695 -30.527
202201 10.650 114.801 11.859
202204 -9.750 118.357 -10.531
202207 -0.450 120.964 -0.476
202210 -1.050 121.517 -1.105
202301 -11.550 121.596 -12.143
202304 -4.800 123.571 -4.966
202307 -2.250 124.914 -2.303
202310 -7.500 125.310 -7.651
202401 -10.650 125.072 -10.885
202404 1.650 126.890 1.662
202407 -1.050 128.075 -1.048
202410 -3.300 127.838 -3.300

Add all the adjusted EPS together and divide 10 will get our e10.


BriaCell Therapeutics  (NAS:BCTX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


BriaCell Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics Business Description

Traded in Other Exchanges
Address
235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Executives
Marc Lustig director 4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3
Jamieson Bondarenko director 402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub director 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin officer: CFO & Secretary MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del officer: Chief Medical Officer 44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams director, officer: President & CEO 620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg director 201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago officer: Chief Scientific Officer 2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony director P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0